Evaluation of Proliferation Parameters in in Vivo Bromodeoxyuridine Labelled Lung Cancers

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 1995 Jan 1

PMID 7496600

Citations 3

Authors

M M Tinnemans

M H Lenders

G P ten Velde

S S Wagenaar

G H Blijham

F C Ramaekers

B Schutte

Affiliations

Soon will be listed here.

Abstract

In a series of 44 bronchial biopsies from patients suspected of having endobronchial lung carcinoma, the validity of proliferating cell nuclear antigen (PCNA) and Ki67 antigen as proliferative indicators was evaluated in ethanol fixed, paraffin embedded tissue. The percentages of cells positive for these markers were compared to the in vivo bromodeoxyuridine (BrdU) labelling index. A good correlation was found between PCNA immunoreactivity and BrdU labelling index, while Ki67-antigen expression showed a significant relation with BrdU labelling index and with PCNA expression. All three parameters showed a trend towards similar values for the individual cases. Based on the fact that Ki67 antigen is expressed in all cycling cells, whereas replicon-associated PCNA and BrdU only reflect the S-phase fraction, the differences between Ki67-antigen scores on the one hand and BrdU and PCNA scores on the other were smaller than expected. In order to determine the degree of concordance between immunohistochemically and flow cytometrically detected proliferation variables, BrdU incorporation was measured using both methods in duplicate bronchial specimens. Discrepancies in labelling indices were observed predominantly in DNA diploid samples, with consistently lower values in the flow cytometrically analysed specimens. In tumour specimens with an aneuploid DNA content, flow cytometric determination of proliferative activity yielded results similar to those obtained by tissue section examination. We conclude that the scores for PCNA and Ki67 antigen, immunohistochemically detected in ethanol fixed, paraffin embedded tissue reflect functional proliferative activity.

Citing Articles

Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy.

Carlin D, Weller A, Kramer G, Liu Y, Waterton J, Chiti A BJR Open. 2020; 1(1):20190029.

PMID: 33178953 PMC: 7592464. DOI: 10.1259/bjro.20190029.

The Presence of Neural Stem Cells and Changes in Stem Cell-Like Activity With Age in Mouse Spiral Ganglion Cells In Vivo and In Vitro.

Moon B, Ammothumkandy A, Zhang N, Peng L, Ibrayeva A, Bay M Clin Exp Otorhinolaryngol. 2018; 11(4):224-232.

PMID: 30309200 PMC: 6222184. DOI: 10.21053/ceo.2018.00878.

Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of oesophageal squamous cell carcinomas.

Okuno Y, Nishimura Y, Kashu I, Ono K, Hiraoka M Br J Cancer. 1999; 80(3-4):387-95.

PMID: 10408843 PMC: 2362322. DOI: 10.1038/sj.bjc.6690368.

References

SUZUKA I, Daidoji H, Matsuoka M, Kadowaki K, Takasaki Y, Nakane P . Gene for proliferating-cell nuclear antigen (DNA polymerase delta auxiliary protein) is present in both mammalian and higher plant genomes. Proc Natl Acad Sci U S A. 1989; 86(9):3189-93. PMC: 287092. DOI: 10.1073/pnas.86.9.3189. View

Verheijen R, Kuijpers H, Schlingemann R, Boehmer A, VAN Driel R, Brakenhoff G . Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase. J Cell Sci. 1989; 92 ( Pt 1):123-30. DOI: 10.1242/jcs.92.1.123. View

Harper M, Goddard L, Wilson D, Matenhelia S, Conn I, Peeling W . Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate. 1992; 20(3):243-53. DOI: 10.1002/pros.2990200309. View

Sasaki K, Kurose A, Ishida Y, Matsuta M . Estimation of S-phase fraction in tumor tissue sections by immunohistochemical staining of PCNA. J Histochem Cytochem. 1994; 42(7):957-60. DOI: 10.1177/42.7.7912251. View

Cattoretti G, BECKER M, Key G, Duchrow M, Schluter C, Galle J . Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992; 168(4):357-63. DOI: 10.1002/path.1711680404. View

Brown D, Gatter K . Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990; 17(6):489-503. DOI: 10.1111/j.1365-2559.1990.tb00788.x. View

Tan C, Castillo C, So A, Downey K . An auxiliary protein for DNA polymerase-delta from fetal calf thymus. J Biol Chem. 1986; 261(26):12310-6. View

Van Dierendonck J, Keijzer R, van de Velde C, Cornelisse C . Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res. 1989; 49(11):2999-3006. View

Baisch H, Gerdes J . Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet. 1987; 20(4):387-91. DOI: 10.1111/j.1365-2184.1987.tb01323.x. View

10.

Leonardi E, Girlando S, Serio G, Mauri F, Perrone G, Scampini S . PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol. 1992; 45(5):416-9. PMC: 495304. DOI: 10.1136/jcp.45.5.416. View

11.

Connolly K, Bogdanffy M . Evaluation of proliferating cell nuclear antigen (PCNA) as an endogenous marker of cell proliferation in rat liver: a dual-stain comparison with 5-bromo-2'-deoxyuridine. J Histochem Cytochem. 1993; 41(1):1-6. DOI: 10.1177/41.1.7678022. View

12.

Fontanini G, Macchiarini P, Pepe S, Ruggiero A, Hardin M, Bigini D . The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer. 1992; 70(6):1520-7. DOI: 10.1002/1097-0142(19920915)70:6<1520::aid-cncr2820700613>3.0.co;2-k. View

13.

Hall P, Woods A . Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Tissue Kinet. 1990; 23(6):505-22. DOI: 10.1111/j.1365-2184.1990.tb01343.x. View

14.

Bravo R, Frank R, Blundell P . Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987; 326(6112):515-7. DOI: 10.1038/326515a0. View

15.

Galand P, Degraef C . Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet. 1989; 22(5):383-92. DOI: 10.1111/j.1365-2184.1989.tb00223.x. View

16.

Bravo R . Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites. J Cell Biol. 1987; 105(4):1549-54. PMC: 2114668. DOI: 10.1083/jcb.105.4.1549. View

17.

ten Velde G, Schutte B, Reijnders M, Bosman F, Blijham G . Cytokinetic analysis of lung cancer by bromodeoxyuridine labeling of cytology specimens. Cytometry. 1989; 10(6):807-10. DOI: 10.1002/cyto.990100621. View

18.

Ogata K, Kurki P, Celis J, Nakamura R, Tan E . Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication. Exp Cell Res. 1987; 168(2):475-86. DOI: 10.1016/0014-4827(87)90020-6. View

19.

Fontana D, Bellina M, Gubetta L, Fasolis G, Rolle L, Scoffone C . Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J Urol. 1992; 148(4):1149-51. DOI: 10.1016/s0022-5347(17)36845-3. View

20.

Waseem N, Lane D . Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci. 1990; 96 ( Pt 1):121-9. DOI: 10.1242/jcs.96.1.121. View